Comparative Pharmacology
Head-to-head clinical analysis: AIRDUO DIGIHALER versus ICOTYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRDUO DIGIHALER versus ICOTYDE.
AIRDUO DIGIHALER vs ICOTYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by increasing cyclic AMP. Fluticasone propionate is a corticosteroid with anti-inflammatory activity that inhibits inflammatory mediators and cells.
ICOTYDE (trifluridine/tipiracil) is a combination of trifluridine, a thymidine-based nucleoside analog that incorporates into DNA and inhibits cell proliferation, and tipiracil, a thymidine phosphorylase inhibitor that increases the systemic exposure of trifluridine by inhibiting its degradation.
Two inhalations (umeclidinium 62.5 mcg and vilanterol 25 mcg per inhalation) orally once daily.
Intravenous: 1000 mg administered over 90 minutes on days 1 and 15 of a 28-day cycle.
None Documented
None Documented
Fluticasone furoate: terminal elimination half-life is approximately 24 hours. Vilanterol: terminal elimination half-life is approximately 11 hours. The long half-life of fluticasone furoate supports once-daily dosing, while vilanterol's half-life allows for sustained bronchodilation over 24 hours.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; may be prolonged in renal impairment.
Fluticasone furoate and vilanterol are primarily eliminated via biliary/fecal routes. For fluticasone furoate, approximately 90% of an oral dose is excreted in feces as parent drug and metabolites, with <1% in urine. Vilanterol is predominantly excreted via feces (∼70%) as metabolites, with ∼20% in urine.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with biliary/fecal elimination contributing the remaining 30%.
Category C
Category C
Inhaled Corticosteroid/LABA Combination
ICS/LABA Combination